The weight loss drug Foundayo, a first-of-its-kind GLP-1 pill approved by the FDA, will be made available through the Trump administration’s pharmaceutical cost comparison website, TrumpRx, CBS News has confirmed.
Foundayo differs from other GLP-1 treatments by not requiring intake on an empty stomach, increasing accessibility for patients who avoid needle-based therapies. The drug was approved under the FDA’s priority voucher program, which accelerates review times from 10-12 months to approximately two months. Foundayo received FDA approval just 50 days after Eli Lilly submitted its filing, with shipping expected to begin April 6, 2026.
TrumpRx, launched by the administration in February 2026, will offer Foundayo to uninsured Americans with launch pricing at $149 for the initial dose. Subsequent refills will be priced at $199, and future prescriptions are expected to cost $299. Meanwhile, the drug will also be sold at similar prices on Eli Lilly’s direct-to-consumer platform, Lilly Direct. However, a White House official told CBS News that TrumpRx is intended to serve as a comprehensive “one stop shop” giving consumers an overview of all GLP-1 options on the market.
Medicare beneficiaries can expect to pay around $50 for the drug, while those with private insurance will pay approximately $25.
Why it matters
Foundayo’s inclusion on TrumpRx represents a significant step in expanding affordable access to weight loss treatments amid growing demand for GLP-1 therapies. The Trump administration’s approach aims to lower prices for uninsured consumers by providing a centralized cost comparison and coupon platform, potentially improving market competition and consumer choice. FDA’s priority review program for Foundayo also highlights efforts to expedite innovative obesity treatments.
Background
GLP-1 drugs have become increasingly popular for managing obesity and related metabolic conditions but often require injections and pose accessibility barriers for some patients. Foundayo’s oral formulation, approved under an accelerated FDA program announced in June 2025, offers a new option in this category.
The Trump administration launched TrumpRx earlier in 2026 as a platform to help Americans compare prescription drug prices and find lower-cost options, especially designed for those without insurance coverage.
Read more Politics stories on Goka World News.